MNK has been the subject of a number of other research reports. Barclays boosted their target price on Mallinckrodt from $12.00 to $20.00 and gave the stock an underweight rating in a research report on Wednesday, August 8th. Zacks Investment Research upgraded Mallinckrodt from a hold rating to a buy rating and set a $33.00 target price for the company in a research report on Wednesday, September 26th. Canaccord Genuity set a $34.00 target price on Mallinckrodt and gave the stock a hold rating in a research report on Sunday, August 19th. Mizuho restated a hold rating and set a $27.00 target price on shares of Mallinckrodt in a research report on Tuesday. Finally, BMO Capital Markets restated an outperform rating and set a $37.00 target price on shares of Mallinckrodt in a research report on Tuesday, August 7th. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating and four have given a buy rating to the company’s stock. Mallinckrodt presently has an average rating of Hold and an average target price of $32.53.
MNK traded down $0.28 during trading on Tuesday, hitting $30.89. The company’s stock had a trading volume of 2,026,671 shares, compared to its average volume of 1,767,710. The company has a debt-to-equity ratio of 0.93, a quick ratio of 2.06 and a current ratio of 2.21. Mallinckrodt has a 12 month low of $11.65 and a 12 month high of $36.65. The company has a market cap of $2.56 billion, a price-to-earnings ratio of 4.12, a PEG ratio of 0.42 and a beta of 1.71.
Mallinckrodt (NYSE:MNK) last released its earnings results on Tuesday, November 6th. The company reported $2.10 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.31. The company had revenue of $640.00 million during the quarter, compared to the consensus estimate of $634.38 million. Mallinckrodt had a return on equity of 9.60% and a net margin of 65.24%. The firm’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.97 earnings per share. As a group, research analysts predict that Mallinckrodt will post 7.09 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Crossmark Global Holdings Inc. bought a new stake in Mallinckrodt in the third quarter valued at about $247,000. Advisors Preferred LLC grew its stake in Mallinckrodt by 493.9% in the second quarter. Advisors Preferred LLC now owns 10,512 shares of the company’s stock valued at $196,000 after acquiring an additional 8,742 shares during the period. Balasa Dinverno & Foltz LLC acquired a new position in Mallinckrodt in the second quarter valued at about $200,000. First Hawaiian Bank acquired a new position in Mallinckrodt in the third quarter valued at about $322,000. Finally, Dupont Capital Management Corp acquired a new position in Mallinckrodt in the third quarter valued at about $322,000.
Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.
Read More: What is the Rule of 72?
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.